View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Sponsored by Pall Corporation

End-to-End Process for Large-Scale Adenovirus Manufacturing

Free White Paper

End-to-End Process for Large-Scale Adenovirus Manufacturing

By Pall Corporation

End-to-End Process for Large-Scale Adenovirus Manufacturing

By Pall Corporation
Enter your details to receive the free paper:

Recent advances in personalised regenerative medicine have been significant. However, further developments are needed to support market and regulatory demands, particularly the development of manufacturing processes to support large scale batches of high-quality viral vectors.

Here, Pall Corporation describes the development of a robust integrated adenoviral manufacturing platform using adherent cells. A step-by-step scalable approach was implemented starting from laboratory scale to develop a fully integrated and reproducible process.

Such a well-controlled operational manufacturing process allowed the production of large amounts of high-quality viral vector in compliance with good manufacturing practice (GMP) requirements suitable for the clinical trials.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology